The amygdala, a relay station for switching on and off pain

European Journal of Pain (United Kingdom)

Volumn 16, Issue 6, 2012, Pages 782-792

  Rouwette, T ^a,b   Vanelderen, P ^a,b,c   Roubos, E W ^a   Kozicz, T ^a   Vissers, K ^b  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; ANTIDEPRESSANT AGENT; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UROCORTIN;

AMYGDALOID NUCLEUS; CELL MEMBRANE; CHRONIC PAIN; HUMAN; HYPERALGESIA; MEDICAL LITERATURE; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

AMYGDALA; ANALGESICS; ANIMALS; CORTICOTROPIN-RELEASING HORMONE; HUMANS; NEURALGIA; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 84867710985     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1002/j.1532-2149.2011.00071.x     Document Type: Review

References (99)

1. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999;160:1-12.
2. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain 2007;23:15-22.
3. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69.
4. Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004;44:525-57.
5. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87-107.
6. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008;165:617-20.
7. Blackburn-Munro G, Blackburn-Munro RE. Chronic pain, chronic stress and depression: coincidence or consequence? J Neuroendocrinol 2001;13:1009-23.
8. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Normal hypothalamo- pituitary-adrenal axis function in a rat model of peripheral neuropathic pain. Brain Res 2005; 1044:216-26.
9. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380-7.
10. Bourbia N, Ansah OB, Pertovaara A. Corticotropin-releasing factor in the rat amygdala differentially influences sensory-discriminative and emotional-like pain response in peripheral neuropathy. J Pain 2010;11:1461-71.
11. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992;267:1244-52.
12. Clatworthy AL, Illich PA, Castro GA, Walters ET. Role of peri-axonal inflammation in the development of thermal hyperalgesia and guarding behavior in a rat model of neuropathic pain. Neurosci Lett 1995;184:5-8.
13. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropinreleasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 2010;27:417-25.
14. Cui XY, Lundeberg T, Yu LC. Role of corticotropin-releasing factor and its receptor in nociceptive modulation in the central nucleus of amygdala in rats. Brain Res 2004; 995:23-8.
15. Da Costa Gomez TM, BehbehaniMM.An electrophysiological characterization of the projection from the central nucleus of the amygdala to the periaqueductal gray of the rat: the role of opioid receptors. Brain Res 1995;689:21-31.
16. Daemen MA, Kurvers HA, Kitslaar PJ, Slaaf DW, Bullens PH, Van Den Wildenberg FA. Neurogenic inflammation in an animal model of neuropathic pain. Neurol Res 1998; 20:41-5.
17. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004;21:976-82.
18. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-22.
19. Davis M, Shi C. The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? Ann N Y Acad Sci 1999;877:281-91.
20. De Souza EB. Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J Neurosci 1987;7:88-100.
21. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000; 87:149-58.
22. Deyama S, Nakagawa T, Kaneko S, Uehara T, Minami M. Involvement of the bed nucleus of the stria terminalis in the negative affective component of visceral and somatic pain in rats. Behav Brain Res 2007;176:367-71.
23. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2011.
24. Dieleman JP, Kerklaan J, Huygen FJ, Bouma PA, Sturkenboom MC. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008;137:681-8.
25. Dong HW, Petrovich GD, Watts AG, Swanson LW. Basic organization of projections from the oval and fusiform nuclei of the bed nuclei of the stria terminalis in adult rat brain. J Comp Neurol 2001;436:430-55.
26. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 1990;15:71-100.
27. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51.
28. Engler H, Doenlen R, Engler A, Riether C, Prager G, Niemi MB, et al. Acute amygdaloid response to systemic inflammation. Brain Behav Immun 2011;25:1384-92.
29. Fields H. State-dependent opioid control of pain. Nat Rev Neurosci 2004;5:565-75.
30. Finnerup NB, Johannesen IL, Sindrup SH, Bach FW, Jensen TS. Pain and dysesthesia in patients with spinal cord injury: A postal survey. Spinal Cord 2001;39:256-62.
31. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20.
32. Frisen J, Risling M, Fried K. Distribution and axonal relations of macrophages in a neuroma. Neuroscience 1993; 55:1003-13.
33. Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster. Arch Intern Med 1997;157:1209-13.
34. Gerashchenko D, Horvath TL, Xie XS. Direct inhibition of hypocretin/orexin neurons in the lateral hypothalamus by nociceptin/orphanin FQ blocks stress-induced analgesia in rats. Neuropharmacology 2011;60:543-9.
35. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets 2006;5:453-79.
36. Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, et al. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci USA 2011;108:3731-6.
37. Hu B, Doods H, Treede RD, Ceci A. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain 2009;143:206-12.
38. Hummel M, Cummons T, Lu P, Mark L, Harrison JE, Kennedy JD, et al. Pain is a salient 'stressor' that is mediated by corticotropin-releasing factor-1 receptors. Neuropharmacology 2010;59:160-6.
39. Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Rev Neurosci 2001;2:83-91.
40. Jesse CR, Wilhelm EA, Nogueira CW. Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. Psychopharmacology (Berl) 2010;212:513-22.
41. Ji G, Fu Y, Ruppert KA, Neugebauer V. Pain-related anxietylike behavior requires CRF1 receptors in the amygdala. Mol Pain 2007;3:13.
42. Ji G, Neugebauer V. Pro- and anti-nociceptive effects of corticotropin-releasing factor (CRF) in central amygdala neurons are mediated through different receptors. J Neurophysiol 2008;99:1201-12.
43. Kasckow JW, Regmi A, Gill PS, Parkes DG, Geracioti TD. Regulation of corticotropin-releasing factor (CRF) messenger ribonucleic acid and CRF peptide in the amygdala: studies in primary amygdalar cultures. Endocrinology 1997;138:4774-82.
44. Kim KJ, Yoon YW, Chung JM. Comparison of three rodent neuropathic pain models. Exp Brain Res 1997;113:200-6.
45. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355-63.
46. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005;6:463-75.
47. Knapp DJ, Whitman BA,Wills TA, Angel RA, Overstreet DH, Criswell HE, et al. Cytokine involvement in stress may depend on corticotrophin releasing factor to sensitize ethanol withdrawal anxiety. Brain Behav Immun 2011;25(Suppl. 1):S146-54.
48. Konat GW, Borysiewicz E, Fil D, James I. Peripheral challenge with double-stranded RNA elicits global up-regulation of cytokine gene expression in the brain. J Neurosci Res 2009;87:1381-8.
49. Kontinen VK, Ahnaou A, Drinkenburg WH, Meert TF. Sleep and EEG patterns in the chronic constriction injury model of neuropathic pain. Physiol Behav 2003;78:241-6.
50. Korosi A, Veening JG, Kozicz T, Henckens M, Dederen J, Groenink L, et al. Distribution and expression of CRF receptor 1 and 2 mRNAs in the CRF over-expressing mouse brain. Brain Res 2006;1072:46-54.
51. Kozicz LT. The activation of urocortin immunoreactive neurons in the Edinger-Westphal nucleus following acute pain stress in rats. Stress 2001;4:85-90.
52. Kozicz T. On the role of urocortin 1 in the non-preganglionic Edinger-Westphal nucleus in stress adaptation. Gen Comp Endocrinol 2007;153:235-40.
53. Kozicz T. The missing link; the significance of urocortin 1/urocortin 2 in the modulation of the dorsal raphe serotoninergic system. Mol Psychiatry 2010;15:340-1.
54. Kozicz T, Bittencourt JC, May PJ, Reiner A, Gamlin PD, Palkovits M, et al. The Edinger-Westphal nucleus: a historical, structural, and functional perspective on a dichotomous terminology. J Comp Neurol 2011a;519:1413-34.
55. Kozicz T, Sterrenburg L, Xu L. Does midbrain urocortin 1 matter? A 15-year journey from stress (mal)adaptation to energy metabolism. Stress 2011b;14:376-83.
56. Lariviere WR, Fiorenzani P, Ceccarelli I, Massafra C, Sorda G, Di Canio C, et al. Central CRH administration changes formalin pain responses in male and female rats. Brain Res 2011;1383:128-34.
57. Lariviere WR, Melzack R. The role of corticotropin-releasing factor in pain and analgesia. Pain 2000;84:1-12.
58. Leung L, Cahill CM. TNF-alpha and neuropathic pain - a review. J Neuroinflammation 2010;7:27.
59. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 2001;98:7570-5.
60. Li C, Vaughan J, Sawchenko PE, Vale WW. Urocortin IIIimmunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J Neurosci 2002;22:991-1001.
61. Li YQ, Jia HG, Rao ZR, Shi JW. Serotonin-, substance P- or leucine-enkephalin-containing neurons in the midbrain periaqueductal gray and nucleus raphe dorsalis send projection fibers to the central amygdaloid nucleus in the rat. Neurosci Lett 1990;120:124-7.
62. Liu X, Eschenfelder S, Blenk KH, Janig W, Habler H. Spontaneous activity of axotomized afferent neurons after L5 spinal nerve injury in rats. Pain 2000;84:309-18.
63. Manas A, Monroy JL, Ramos AA, Cano C, Lopez-Gomez V, Masramon X, et al. Prevalence of neuropathic pain in radiotherapy oncology units. Int J Radiat Oncol Biol Phys 2011;81:511-20.
64. Maves TJ, Pechman PS, Gebhart GF, Meller ST. Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in man. Pain 1993;54:57-69.
65. McNally GP, Akil H. Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. Neuroscience 2002; 112:605-17.
66. McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain 2003;106:127-33.
67. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 2004;111:77-83.
68. Merchenthaler I, Vigh S, Petrusz P, Schally AV. Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Am J Anat 1982;165:385-96.
69. Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474.
70. Olsson Y. Degranulation of mast cells in peripheral nerve injuries. Acta Neurol Scand 1967;43:365-74.
71. Perry VH, Brown MC, Gordon S. The macrophage response to central and peripheral nerve injury. A possible role for macrophages in regeneration. J Exp Med 1987;165:1218-23.
72. Raber J, Koob GF, Bloom FE. Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response. J Pharmacol Exp Ther 1995;272:815-24.
73. Regev L, Neufeld-Cohen A, Tsoory M, Kuperman Y, Getselter D, Gil S, et al. Prolonged and site-specific overexpression of corticotropin-releasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Mol Psychiatry 2011;16:714-28.
74. Ro LS, Chang KH. Neuropathic pain: mechanisms and treatments. Chang Gung Med J 2005;28:597-605.
75. Roeska K, Ceci A, Treede RD, Doods H. Effect of high trait anxiety on mechanical hypersensitivity in male rats. Neurosci Lett 2009;464:160-4.
76. Roeska K, Doods H, Arndt K, Treede RD, Ceci A. Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. Pain 2008; 139:349-57.
77. Rouwette T, Klemann K, Gaszner B, Scheffer GJ, Roubos EW, Scheenen WJ, et al. Differential responses of corticotropin-releasing factor and urocortin 1 to acute pain stress in the rat brain. Neuroscience 2011a;183:15-24.
78. Rouwette T, Vanelderen P, Reus MD, Loohuis NO, Giele J, Egmond JV, et al. Experimental neuropathy increases limbic forebrain CRF. Eur J Pain 2011b.
79. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990;43:205-18.
80. Sherbourne CD, Asch SM, Shugarman LR, Goebel JR, Lanto AB, Rubenstein LV, et al. Early identification of co-occurring pain, depression and anxiety. J Gen Intern Med 2009;24:620-5.
81. Smagin GN, Dunn AJ. The role of CRF receptor subtypes in stress-induced behavioural responses. Eur J Pharmacol 2000;405:199-206.
82. Sommer C, Galbraith JA, Heckman HM, Myers RR. Pathology of experimental compression neuropathy producing hyperesthesia. J Neuropathol Exp Neurol 1993;52:223-33.
83. Steckler T. The molecular neurobiology of stress-evidence from genetic and epigenetic models. Behav Pharmacol 2001;12:381-427.
84. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006; 7:281-9.
85. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5.
86. Tsatsanis C, Dermitzaki E, Venihaki M, Chatzaki E, Minas V, Gravanis A, et al. The corticotropin-releasing factor (CRF) family of peptides as local modulators of adrenal function. Cell Mol Life Sci 2007;64:1638-55.
87. Ulrich-Lai YM, Xie W, Meij JT, Dolgas CM, Yu L, Herman JP. Limbic and HPA axis function in an animal model of chronic neuropathic pain. Physiol Behav 2006;88:67-76.
88. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213:1394-7.
89. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000;428:191-212.
90. Vissers KC. The clinical challenge of chronic neuropathic pain. Disabil Rehabil 2006;28:343-9.
91. Vit JP, Clauw DJ, Moallem T, Boudah A, Ohara PT, Jasmin L. Analgesia and hyperalgesia from CRF receptor modulation in the central nervous system of Fischer and Lewis rats. Pain 2006;121:241-60.
92. Wall PD, Devor M, Inbal R, Scadding JW, Schonfeld D, Seltzer Z, et al. Autotomy following peripheral nerve lesions: experimental anaesthesia dolorosa. Pain 1979; 7:103-11.
93. Waselus M, Nazzaro C, Valentino RJ, Van Bockstaele EJ. Stress-induced redistribution of corticotropin-releasing factor receptor subtypes in the dorsal raphe nucleus. Biol Psychiatry 2009;66:76-83.
94. Wittmann G, Fuzesi T, Liposits Z, Lechan RM, Fekete C. Distribution and axonal projections of neurons coexpressing thyrotropin-releasing hormone and urocortin 3 in the rat brain. J Comp Neurol 2009a;517:825-40.
95. Wittmann G, Fuzesi T, Singru PS, Liposits Z, Lechan RM, Fekete C. Efferent projections of thyrotropin-releasing hormone-synthesizing neurons residing in the anterior parvocellular subdivision of the hypothalamic paraventricular nucleus. J Comp Neurol 2009b;515:313-30.
96. Xie Y, Zhang J, Petersen M, LaMotte RH. Functional changes in dorsal root ganglion cells after chronic nerve constriction in the rat. J Neurophysiol 1995;73:1811-20.
97. Yarushkina NI. The role of hypothalamo-hypophysealadrenocortical system hormones in controlling pain sensitivity. Neurosci Behav Physiol 2008;38:759-66.
98. Zorrilla EP, Koob GF. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 2004;13:799-828.
99. Zorrilla EP, Koob GF. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 2010;15:371-83.